Please use this identifier to cite or link to this item:
Title: Inpatient management of gamma-hydroxybutyrate withdrawal
Authors: Murnion, Bridin ;Cappetta, M.
Affliation: Central Coast Local Health District
Wyong Hospital
Issue Date: Jun-2019
Source: 27(3):284-287
Journal title: Australasian Psychiatry
Department: Drug & Alcohol
Abstract: OBJECTIVES: To describe the baseline characteristics, treatment and retention in patients electively admitted for gamma-hydroxybutyrate (GHB) withdrawal management. METHODS: All patients admitted between July 2010 to June 2016 who used GHB two or more times per week with a minimum duration of 3 months were identified and data extracted by file review. RESULTS: Twelve cases satisfied the inclusion criteria, of whom 50% were female; 75% were using GHB daily, with an average daily amount of 16 ml. Average duration of use was 60 months. All subjects were using amphetamine type stimulants and nicotine. Psychiatric comorbidity and unintentional overdose were common; 50% completed treatment. Medications used included diazepam and neuroleptic. Two patients completed withdrawal with no medications. No subject using greater than 90 ml GHB in the preceding week completed treatment. Pattern of GHB use did not predict medication requirements during withdrawal management. CONCLUSIONS: There were low numbers attending for elective treatment for GHB use. Heavier GHB use predicted poor treatment retention. Polysubstance use and psychiatric co-morbidities need consideration in treatment planning.
DOI: 10.1177/1039856218822748
ISSN: 1039-8562
Publicaton type: Journal Article
Keywords: Drug and Alcohol
Mental Health
Appears in Collections:Mental Health

Show full item record

Page view(s)

checked on Jan 27, 2023

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.